Allschwil, Switzerland – Idorsia Ltd (SIX: IDIA) today announced the initiation of FAB-KLEAR, the pivotal Phase 3 kidney biopsy study of lucerastat in adult patients with Fabry disease, and a co-development and commercialization agreement with Nxera Pharma Co., Ltd. (Nxera). The agreement strengthens the global development of lucerastat through shared investment...

Basel, Switzerland – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the global launch of the VENTANA BAP1 (SP527)* test. This automated, ready-to-use immunohistochemistry (IHC) assay provides a reliable, highly specific diagnostic tool to help clinicians and pathologists accurately identify mesothelioma and distinguish it from other malignancies, including non-small cell...

PASADENA, Calif. — Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that adults in England and Wales who live with a rare metabolic condition called Familial Chylomicronaemia Syndrome (FCS) will have access to a newly licensed new treatment option available on the NHS to reduce extremely high levels of triglycerides (a...